What's new? Log in Free sign up

Travere Therapeutics (TVTX) News and press releases

Company Profile

News

From Benzinga Pro

Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside

Analyst Color, Biotech, News, Health Care, Price Target, Initiation, Small Cap, Analyst Ratings, Movers, Trading Ideas, General

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Guggenheim Initiates Coverage On Travere Therapeutics with Buy Rating, Announces Price Target of $37

News, Price Target, Initiation, Analyst Ratings

Guggenheim analyst Vamil Divan initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Buy rating and announces Price Target of $37.

Reported Late Tuesday Feb. 28, Travere Therapeutics Announces Pricing Of $200M Upsized Public Offering Of 8.275M Shares Of Common Stock At A Price Of $21/Share And 1.25M Pre-Funded Warrants

News, Offerings

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of

Travere Therapeutics's Return On Capital Employed Overview

Canaccord Genuity Maintains Buy on Travere Therapeutics, Lowers Price Target to $42

News, Price Target, Analyst Ratings

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $44 to $42.

Travere Therapeutics Announces Proposed Public Offering Of $175M Shares Of Common Stock

News, Offerings

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175,000,000 of its common stock. All

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $40 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $40 price target.

Travere Therapeutics Q4 EPS $(0.76) Beats $(1.07) Estimate, Sales $55.87M Beat $53.01M Estimate

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.07) by 28.97 percent. This is a 24.59 percent decrease over losses of $(0.61) per share

Earnings Scheduled For February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Travere Therapeutics's Earnings Outlook

What 10 Analyst Ratings Have To Say About Travere Therapeutics

Analyst Ratings

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $44

News, Price Target, Analyst Ratings

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $40 to $44.

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $46

News, Price Target, Analyst Ratings

Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $42 to $46.

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General

Wedbush Upgrades Travere Therapeutics to Outperform, Announces $30 Price Target

News, Upgrades, Price Target, Analyst Ratings

Wedbush analyst Laura Chico upgrades Travere Therapeutics (NASDAQ:TVTX) from Neutral to Outperform and announces $30 price target.

Press releases

From Benzinga Pro

Travere Therapeutics to Present at Upcoming Investor Conferences

News, Health Care, Press Releases

SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim Healthcare Talks |

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

News, Press Releases

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Markets, Press Releases

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on March 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023

News, Health Care, Press Releases

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the Company will present a quantitative systems pharmacology (QSP) model for predicting the effects of the

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Markets, Press Releases

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Markets, Press Releases

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions,

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Earnings, Press Releases

Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN) European Medicines Agency

Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Health Care, Press Releases, General

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

News, Press Releases

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the close

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Markets, Press Releases

SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on February 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to

Travere Therapeutics to Present at Upcoming Investor Conferences

News, Press Releases

SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: SVB Securities Global Biopharma

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on January 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

News, Press Releases

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.